Dulles, Virginia, March 2, 2012 – IBA Molecular North America, Inc. (IBA) has announced the introduction of SureStart™, an innovative peer review system for NaF PET/CT bone imaging programs. SureStart is designed to help sites effectively establish NaF PET/CT imaging services by fostering quality assurance, staff capability and confidence, and enhanced value to the referring physician community.
SureStart provides direct educational support for PET/CT interpreters with a web-enabled system providing expert peer review for equivocal or challenging NaF PET/CT cases. With minimal configuration and installation requirements, SureStart delivers expert feedback, within approximately 24 hours, on interpretive agreement, as well as technical quality aspects, such as windowing, use of CT co- registration, MIP evaluation, etc. Complementing this service is an introductory educational package dedicated to providing reading physicians with the basics of NaF PET/CT imaging to support interpretation. Included is a narrated reader training presentation, instructional videos on windowing techniques and image processing, illustrative case studies, as well as a NaF PET/CT reporting template. Implementation of SureStart can assist imaging centers in providing quality service, delivering value to their referring community, and experiencing accelerated program growth.
SureStart is an important adjunct to IBA’s NaF Education Best Practices Framework, an all-inclusive education and marketing plan to successfully launch and grow NaF PET/CT bone imaging programs within the referring community. By taking advantage of IBA’s support services, clients are poised for more rapid and sustainable growth in their NaF programs. IBA’s market leadership in 18F Sodium Fluoride is evidence that these programs work.
SureStart is part of IBA’s PETLinQ suite of products, all of which are designed to support and enhance PET imaging programs. PETLinQ IQ is an innovative PET educational web portal, available to all IBA customers. PETLinQ WD is a cost-effective, web-enabled image distribution and archive system, designed to improve connectivity between the imaging site and the referring community. For more information on SureStart, including IBA’s complimentary introductory peer review offering, contact your regional IBA Clinical Account Executive, or go to http://www.iba-molecular.com
ABOUT IBA
IBA Molecular North America, Inc. is part of Ion Beam Applications S.A. (IBA SA) Molecular Tracers business unit. IBA Molecular is a global developer, manufacturer and distributor of radiopharmaceutical products and supporting services used in molecular imaging. IBA Molecular has engineered a strong and unique product portfolio and pipeline of diagnostic tracers aimed at contributing to the development of the global trend towards personalized medicine and making molecular imaging a major discipline in healthcare. The company also provides educational, technical and marketing support to medical specialists worldwide to help better respond to patient needs. IBA SA develops and markets leading-edge technologies, pharmaceuticals and tailor-made solutions for healthcare with a focus on cancer diagnosis and therapy. Leveraging its scientific expertise, IBA SA is also active in the field of industrial sterilization and ionization. Listed on the pan-European stock exchange EURONEXT, IBA SA is included in the BelMid Index. (IBA:Reuters IBAB.BR and Bloomberg IBAB.BB).
Please visit www.iba-molecular.com and www.iba-molecular.com for more information about IBA Molecular and IBA SA.
CONTACT:
IBA
Randall Mastrangelo
Vice President, Marketing
IBA Molecular North America, Inc.
Randall.Mastrangelo@iba-group.com
